Genomic life science company EZZ Life Science Holdings Ltd (ASX:EZZ) is set to hit the US market for products in the ‘food’ category, being granted approval from the country’s Food and Drug Administration (FDA) for nine of these.
And the market seems impressed by the news, with EZZ shares sitting at $1.45 cents by 13:09 AEDT, a rise of 15.54 percent since the market opened.
The company is hoping to take advantage of the rich market for health supplements in the United States, with online sales of these reaching US$23.8 billion last year, through the sales of its Children’s Essential Minerals, Children’s Eye Health, Bone Growth Chews, Brain Focus, Magnesium Plus, Aloe Vera Probiotic Capsules, Liver Detox, Joint Energy Boost Tablets and Men’s Performance products.
EZZ chairman Glenn Cross said the company was delighted to have achieved this milestone.
“This is a monumental achievement for EZZ and a validation of our commitment to excellence in product quality and innovation,” he said.
“Entering the US market is a pivotal part of our plans for future growth, and we are excited about the opportunities this approval presents.
“We look forward to bringing our high-quality products to consumers in the United States and continuing to drive value for our shareholders.”